Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ZOMETA
- Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Women
- Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate
- Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer
- Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
- Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding
- 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
- Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer
- Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
- Pre-operative Zoledronate in Triple Negative Breast Cancer
- Prevention of Bone Loss After Acute SCI by Zoledronic Acid
- Prolonged Protection From Bone Disease in Multiple Myeloma
- Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
- Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
- Zoledronic Acid Administration in Acute Spinal Cord Injury
- Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
- The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
- Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
- Zometa Study in Pediatric Acute Lymphoblastic Leukemia
- Bone Loss Treatment From Adjuvant Zoledronate Efficacy
- Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa
- ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
- Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
- Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
- Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers
- The Efficacy of Zoledronic Acid in Modic Changes-related Low Back Pain (LBP)
- PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
- Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
- Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
- Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
- Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
- Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
- Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
- Study in Localized and Disseminated Ewing Sarcoma
- Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
- Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
- Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients
- Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
- Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
- Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
- N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
- Zoledronate for Osteopenia in Pediatric Crohn's
- Personalized Treatment Selection for Metastatic Breast Cancer
- Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
- Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
- Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
- Stage I Multiple Myeloma Treatment
- Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
- To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
- Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
- Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
- Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
- Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
- Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
- Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
- Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
- Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
- Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
- Zoledronic Acid for Osteoporosis in the Elderly
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
- Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
- Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
- Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
- Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
- Zoledronate With Atorvastatin in Renal Cell Carcinoma
- Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
- ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
- Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
- Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
- Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
- Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
- Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
- Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
- Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
- A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
- Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
- Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
- Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
- Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
- Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
- ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
- A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
- Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
- Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
- Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis
- Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
- Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
- Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
- Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
- Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
- Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
- Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
- Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
- Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
- Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
- Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
- Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
- Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
- Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
- Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
- Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
- Vitamin K and Bone Turnover in Postmenopausal Women
- An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
- Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
- Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
- Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
- Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Clinical trials list
click for details